Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 10/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958891 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29524384 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL28525054 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29366953 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29390151 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL29523882 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL3740313 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL13388428 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL19464901 | 0.93 | ADORA3 (0.87) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 | |
| SCHEMBL20122154 | 0.93 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132131-B2 | Use of adenosine A3 receptor agonists for treatment of neuropathic pain | SAINT LOUIS UNIVERSITY (US) | 2015-09-15 | — | — | US | claimed |
| US-20120270829-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-25 | — | — | US | claimed |
| US-7867983-B2 | Methods to protect skeletal muscle against injury | THE UNIVERSITY OF CONNECTICUT (US) | 2011-01-11 | — | — | US | claimed |
| US-20080312180-A1 | Methods to Protect Skeletal Muscle Against Injury | The U.S.A, as Represented by The Secretary of the Army, on Behalf of the U.S. Army Research | 2008-12-18 | — | — | US | claimed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12397010-B2 | Treatment of chronic headaches | SAINT LOUIS UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011123518-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| US-7867983-B2 | Methods to protect skeletal muscle against injury | THE UNIVERSITY OF CONNECTICUT (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2008156513-A2 | METHODS TO PROTECT SKELETAL MUSCLE AGAINST INJURY | UNIVERSITY OF CONNECTICUT (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312180-A1 | Methods to Protect Skeletal Muscle Against Injury | The U.S.A, as Represented by The Secretary of the Army, on Behalf of the U.S. Army Research | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312180-A1 | Methods to Protect Skeletal Muscle Against Injury | MUSK, TNNI3, TNNC1 | ADORA3 18/4885ADORA1 33/4885ADORA2A 17/4885 |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | ADORA3 3/4885ADORA1 11/4885ADORA2A 1/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885ADORA2A 1/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | ADORA3 1076/4885ADORA1 499/4885ADORA2A 1017/4885 |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885ADORA2A 436/4885 |
| US-12397010-B2 | Treatment of chronic headaches | ADORA3, ADORA2B, ADORA2A | ADORA3 1/4885ADORA1 10/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.